Biogen’s Alzheimer’s Drug Aduhelm Price Cut in Half

After months of controversy and underwhelming opening sales, Biogen has cut the price of it’s Alzheimer’s drug Aduhelm in half from $56,000 a year to $28200. The manufacturer hopes this will encourage insurance companies to cover the drug. The move comes shortly before Medicare releases a draft decision later this month on whether the drug will be covered.

Adam Fueurstein of Stat News adds that, “…with Aduhelm delivering paltry revenue, Biogen is also being forced to downsize the company. On Monday, Biogen said it would implement a series of cost-cutting measures in 2022 that are expected to total approximately $500 million. Details will be announced in the first quarter. STAT has previously reported that Biogen was assembling a restructuring plan that calls for more than 1,000 Biogen employees to lose their jobs early next year.”

Learn more by clicking here.

(Source: Biogen, December 20^th, 2021)